The Abbott ID NOW™ COVID-19 assay has received Emergency Use Authorization (EUA) from the U.S Food and Drug Administration (FDA). ID NOW™ COVID-19 assay performed on the ID NOW Instrument is a rapid molecular in vitro diagnostic test utilizing an isothermal nucleic acid amplification technology intended for the qualitative detection of nucleic acid from the SARS-CoV-2 viral RNA in direct nasal, nasopharyngeal or throat swabs and nasal, nasopharyngeal or throat swabs eluted in viral transport media from individuals who are suspected of COVID-19 by their healthcare provider. Testing is authorized for laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate complexity/high complexity tests. The ID NOW™ COVID-19 assay is also authorized to be distributed and used in patient care settings outside of the clinical laboratory environment. Please contact your Abbott Rapid Diagnostics Account Executive if you are interested in acquiring an ID NOW™ instrument.